NCT00697203View on ClinicalTrials.gov

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

PHASE2CompletedINTERVENTIONAL

Enrollment

292

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions

Dyslipidemia

Interventions

DRUG

Placebo

po daily for 12 weeks

DRUG

Pravastatin

40mg po daily for 12 weeks

DRUG

Dalcetrapib

300mg po daily for 12 weeks

DRUG

Dalcetrapib

600mg po daily for 12 weeks

DRUG

Dalcetrapib

900mg po daily for 12 weeks

Trial Locations (33)

18974

Warminster

19107

Philadelphia

19713

Newark

20817

Bethesda

21201

Baltimore

21204

Towson

23294

Richmond

27103

Winston-Salem

28209

Charlotte

28677

Statesville

33137

Miami

36608

Mobile

40213

Louisville

45212

Cincinnati

45246

Springdale

46260

Indianapolis

47714

Evansville

52242

Iowa City

53719

Madison

63110

St Louis

66215

Overland Park

67207

Wichita

70043

Chalmette

70458

Slidell

73103

Oklahoma City

76107

Fort Worth

77030

Houston

85251

Scottsdale

98104

Seattle

60610-4319

Chicago

04210

Auburn

04074

Scarborough

03301

Concord

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00697203 - A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C) | Biotech Hunter | Biotech Hunter